Home › Neuroblastoma › Georgia
Neuroblastoma clinical trials in Georgia
9 studies for Neuroblastoma are looking for participants at sites in Georgia.
Cities in Georgia
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- Children's Healthcare of Atlanta, Atlanta
Recruiting
Up to age 17 · All sexes · Updated Nov 13, 2026 · NCT06831552Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Memorial Health University Medical Center, Savannah
RecruitingPhase 3
Up to age 30 · All sexes · Updated Oct 30, 2026 · NCT06172296Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Augusta University Health, Augusta
RecruitingPhase 2
Up to age 22 · All sexes · Updated Sep 4, 2026 · NCT02559778Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Memorial Health University Medical Center, Savannah
RecruitingPhase 3
365 Days – 30 Years · All sexes · Updated Aug 25, 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Augusta University Health, Augusta
RecruitingPhase 2
12 Months – 21 Years · All sexes · Updated Aug 12, 2026 · NCT05489887Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Children's Healthcare of Atlanta/Emory University School of Medicine, Atlanta
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702Neuroblastoma Biology Study
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta
RecruitingObservational study
31 Days – 99 Years · All sexes · Updated Mar 23, 2026 · NCT01587300Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
- Children's Healthcare of Atlanta, Atlanta
RecruitingPhase 1
12 Months · All sexes · Updated Dec 26, 2025 · NCT05400603From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.